Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells.

IF 2.3 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomedical reports Pub Date : 2023-07-01 DOI:10.3892/br.2023.1629

Jun Lu, Xiaowu Jenifer Wu, Amira Hassouna, Kelvin Sheng Wang, Yan Li, Tao Feng, Yu Zhao, Minfeng Jin, Baohong Zhang, Tianlei Ying, Jinyao Li, Lufeng Cheng, Johnson Liu, Yue Huang

{"title":"Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells.","authors":"Jun Lu, Xiaowu Jenifer Wu, Amira Hassouna, Kelvin Sheng Wang, Yan Li, Tao Feng, Yu Zhao, Minfeng Jin, Baohong Zhang, Tianlei Ying, Jinyao Li, Lufeng Cheng, Johnson Liu, Yue Huang","doi":"10.3892/br.2023.1629","DOIUrl":null,"url":null,"abstract":"<p><p>Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.</p>","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"19 1","pages":"46"},"PeriodicalIF":2.3000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/49/41/br-19-01-01629.PMC10265583.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/br.2023.1629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 2

Abstract

Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.

Abstract Image

查看原文本刊更多论文

吉西他滨-岩藻黄素组合在人胰腺癌细胞中的作用。

吉西他滨是一种用于胰腺癌治疗的化疗药物。它也被证明可以抑制人胰腺癌细胞系MIA PaCa-2和PANC-1。本研究的目的是研究岩藻黄素，一种海洋类胡萝卜素，联合吉西他滨对胰腺癌细胞的抑制作用。通过MTT实验和流式细胞术细胞周期分析来研究其作用机制。结果表明，低剂量岩藻黄素联合吉西他滨可增强人胚胎肾细胞293的细胞活力，而高剂量岩藻黄素可增强吉西他滨对该细胞系细胞活力的抑制作用。岩藻黄素增强了吉西他滨对PANC-1细胞的抑制作用(P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical reports MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： Biomedical Reports is a monthly, peer-reviewed journal, dedicated to publishing research across all fields of biology and medicine, including pharmacology, pathology, gene therapy, genetics, microbiology, neurosciences, infectious diseases, molecular cardiology and molecular surgery. The journal provides a home for original research, case reports and review articles.